For the safety of our patients and staff, we have updated our visitor policy, effective December 27. This includes important information about COVID-19 vaccination or testing for some visitors. Read the latest information for visitors.
Fei Ye, PhD
Director, Assay Development
Molecular Diagnostics in Clinical Oncology, Bone Marrow Transplantation Monitoring, and HLA-Associated Diseases; Molecular Genetics; Molecular Virology
MS, Norman Bethune University of Medical Sciences, Changchun, China; PhD, Norman Bethune University of Medical Sciences, Changchun, China
Molecular Immunology - Tongji Medical University, Wuhan, China
New York State Department of Health Certificate of Qualification in Transplant Monitoring, Oncology, Virology, and Molecular Genetics
I am a clinical laboratory scientist and have almost 20 years of clinical expertise in molecular biology, assay development, and validation of laboratory developed tests. Over the years, I have developed, validated, and implemented clinical molecular assays in transplant monitoring, oncology, infectious diseases, and genetics. In addition, I have a demonstrated record of successful and productive research and translational projects in areas of high relevance for cancer biology. As Director of Assay Development, I lead the technical direction of validating and implementing HLA-related molecular tests in the Immunogenomics of Transplantation and Cellular Therapy Laboratory, as well as expanding the department’s clinical and translational research innovation. This includes work such as molecular and proteomic biomarker discovery, circulating micro RNA-based assays, and next-generation sequencing.
My research has been mainly focused on therapeutic and diagnostic biomarker discovery. Through my work I have seen that that dysregulation of a network of protein-protein interactions (rather than one or a few proteins) in a cell leads to transformation, invasion, and metastasis of the cancer cells, and each subnetwork presents a different phenotype of cancer. I have a strong interest in collaborating with MSK clinical investigators to study the signaling pathways and networks that are targeted by cancer development and progression of anticancer drugs. We are working to further identify biomarkers and druggable targets for cancer diagnosis and treatment.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Fei Ye discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at email@example.com.